
HRMY Stock Forecast & Price Target
HRMY Analyst Ratings
Bulls say
Harmony Biosciences Holdings Inc. demonstrates strong growth potential, with projections indicating that WAKIX sales in narcolepsy could surge from approximately $160 million in 2020 to over $700 million by 2024, driven by the drug's safety and convenience advantages. Additionally, the company's promising pipeline includes innovative candidates like pitolisant-GR, which is designed to enhance treatment adherence among patients by eliminating dose titration, potentially leading to a new drug application filing in early 2026. Furthermore, Harmony's strategic patent filings could extend exclusivity for its products through 2044, ensuring long-term value and a robust market position beyond the anticipated 2030 loss of exclusivity for WAKIX.
Bears say
Harmony Biosciences Holdings Inc. faces significant risks that contribute to a negative outlook on its stock. The potential entry of new competitors in the sodium oxybate market, combined with a slower-than-expected rate of new patient additions for WAKIX, could hinder the product's growth trajectory. Additionally, the uncertainty surrounding the outcomes of ongoing clinical trials for various indications raises concerns about the company's ability to expand its pipeline successfully.
This aggregate rating is based on analysts' research of Harmony Biosciences Holdings and is not a guaranteed prediction by Public.com or investment advice.
HRMY Analyst Forecast & Price Prediction
Start investing in HRMY
Order type
Buy in
Order amount
Est. shares
0 shares